| Peter Vincent Lopez, MD | |
|
560 S Lakewood Dr Ste 101, Brandon, FL 33511-5015 | |
| (813) 978-9700 | |
| (813) 558-6186 |
| Full Name | Peter Vincent Lopez |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 33 Years |
| Location | 560 S Lakewood Dr Ste 101, Brandon, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366404550 | NPI | - | NPPES |
| 258811100 | Medicaid | FL | |
| MB781 | Other | FL | MEDICARE FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | ME76340 (Florida) | Primary |
| 207XS0106X | Orthopaedic Surgery - Hand Surgery | ME76340 (Florida) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health | Bradenton, FL | Home health agency |
| South Bay Hospital | Sun city center, FL | Hospital |
| St Josephs Hospital | Tampa, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sports And Orthopedic Rehabilitation Services Inc | 0840104253 | 192 |
| Florida Orthopaedic Institute | 1052224102 | 308 |
News Archive
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
The President of the U.S. Chamber of Commerce was greeted in Philadelphia today by a coalition demanding that he end his campaign against health care and clean energy reform.
Despite advances in neonatal care, necrotizing enterocolitis (NEC) - the most common gastrointestinal emergency in premature infants - continues to be a deadly disease. "We haven't made a lot of progress in identifying babies early who may be at risk for NEC, preventing it or treating it," said J-rn-Hendrik Weitkamp, M.D., a neonatologist and assistant professor of Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt.
The fight against antibiotic-resistant superbugs has taken a step forward thanks to a new discovery by scientists at The University of Nottingham.
› Verified 9 days ago
| Entity Name | Musculoskeletal Institute Chartered |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386639920 PECOS PAC ID: 1052224102 Enrollment ID: O20031106000215 |
News Archive
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
The President of the U.S. Chamber of Commerce was greeted in Philadelphia today by a coalition demanding that he end his campaign against health care and clean energy reform.
Despite advances in neonatal care, necrotizing enterocolitis (NEC) - the most common gastrointestinal emergency in premature infants - continues to be a deadly disease. "We haven't made a lot of progress in identifying babies early who may be at risk for NEC, preventing it or treating it," said J-rn-Hendrik Weitkamp, M.D., a neonatologist and assistant professor of Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt.
The fight against antibiotic-resistant superbugs has taken a step forward thanks to a new discovery by scientists at The University of Nottingham.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter Vincent Lopez, MD 560 S Lakewood Dr Ste 101, Brandon, FL 33511-5015 Ph: (813) 978-9700 | Peter Vincent Lopez, MD 560 S Lakewood Dr Ste 101, Brandon, FL 33511-5015 Ph: (813) 978-9700 |
News Archive
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
The President of the U.S. Chamber of Commerce was greeted in Philadelphia today by a coalition demanding that he end his campaign against health care and clean energy reform.
Despite advances in neonatal care, necrotizing enterocolitis (NEC) - the most common gastrointestinal emergency in premature infants - continues to be a deadly disease. "We haven't made a lot of progress in identifying babies early who may be at risk for NEC, preventing it or treating it," said J-rn-Hendrik Weitkamp, M.D., a neonatologist and assistant professor of Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt.
The fight against antibiotic-resistant superbugs has taken a step forward thanks to a new discovery by scientists at The University of Nottingham.
› Verified 9 days ago
Anjan R Shah, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 560 S Lakewood Dr Ste 101, Brandon, FL 33511 Phone: 813-978-9700 Fax: 813-558-6434 | |
Dr. Matthew Richard Moralle, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 615 Vonderburg Dr, Brandon, FL 33511 Phone: 813-684-2663 Fax: 813-441-7161 | |
Evan Michael Loewy, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 560 S Lakewood Dr Ste 101, Brandon, FL 33511 Phone: 813-978-9700 Fax: 813-558-6186 | |
Michael A Miranda, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 305 E Brandon Blvd, Brandon, FL 33511 Phone: 813-978-9700 Fax: 813-558-6432 | |
Dr. Keith J Simon, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 230 S Moon Ave, Brandon, FL 33511 Phone: 813-571-6311 Fax: 813-571-6350 | |
Dr. Neil Kumar, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 560 S Lakewood Dr Ste 101, Brandon, FL 33511 Phone: 813-978-9700 Fax: 813-558-6186 |